March 2026 DifGen Pharmaceuticals received U.S. FDA approval for Mesalamine Extended-Release Capsules USP, 250 mg and 500 mg, a generic equivalent to Pentasa. The approval expanded DifGen's portfolio of complex controlled-release oral formulations for ulcerative colitis treatment.
November 2025 Zydus Lifesciences received final U.S. FDA approval for Diroximel Fumarate Delayed-Release Capsules, 231 mg. The enteric delayed-release product is indicated for relapsing forms of multiple sclerosis and will be manufactured at Zydus' SEZ facility.
October 2025 Akums Drugs & Pharmaceuticals secured a 20-year patent for a dual-release gastro-resistant composition. The patented formulation uses dual-release technology designed to deliver active ingredients at different intestinal sites, strengthening the company's gastro-resistant and modified-release drug delivery capabilities.
June 2025 Colorcon received the 2025 CPHI China Market Impact Award for its Opadry Complete Film Coating System, recognizing its pharmaceutical tablet coating technology and formulation capabilities.